Transcutaneous Cervical Vagal Nerve Stimulation Blocks Sympathetic Responses to Stress in Posttraumatic Stress Disorder

Authors: Nil Z. Gurel, MS\textsuperscript{1,*}, Matthew T. Wittbrodt, PhD\textsuperscript{2}, Hewon Jung, MS\textsuperscript{1}, Md. Mobashir H. Shandhi, MS\textsuperscript{1}, Emily G. Driggers, MA\textsuperscript{2}, Stacy L. Ladd, MA\textsuperscript{2,3}, Minxuan Huang, MS\textsuperscript{4}, Yi-An Ko, PhD\textsuperscript{5}, Lucy Shallenberger, MPH\textsuperscript{4}, Joy Beckwith, PhD, MPH\textsuperscript{2}, Jonathon A. Nye, PhD\textsuperscript{3}, Bradley D. Pearce, PhD\textsuperscript{4}, Viola Vaccarino, MD, PhD\textsuperscript{4,6}, Amit J. Shah, MD, MSCR\textsuperscript{4,6,7}, Omer T. Inan, PhD\textsuperscript{1,8}, J. Douglas Bremner, MD\textsuperscript{2,3,7}

\textsuperscript{1}School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA.

\textsuperscript{2}Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA.

\textsuperscript{3}Department of Radiology, Emory University School of Medicine, Atlanta, GA.

\textsuperscript{4}Department of Epidemiology, Rollins School of Public Health, Atlanta, GA.

\textsuperscript{5}Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Atlanta, GA.

\textsuperscript{6}Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA.

\textsuperscript{7}Atlanta VA Medical Center, Decatur, GA.

\textsuperscript{8}Coulter Department of Bioengineering, Georgia Institute of Technology, Atlanta, GA.

*Corresponding author. E-mail: nil@gatech.edu. Address: 85 5\textsuperscript{th} St NW, Atlanta, GA, 30308

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract:

Objective: Exacerbated autonomic responses to acute stress are prevalent in posttraumatic stress disorder (PTSD). The purpose of this study was to assess the effects of transcutaneous cervical VNS (tcVNS) on autonomic responses to acute stress in patients with PTSD. The authors hypothesized tcVNS would reduce the sympathetic response to stress compared to a sham device.

Methods: Using a randomized double-blind approach, the effects of tcVNS on physiological responses to stress were investigated in patients with PTSD (n=25) using noninvasive sensing modalities. Participants received either sham or active tcVNS after exposure to acute personalized traumatic script stress and mental stress (public speech, mental arithmetic) over a three-day protocol. Physiological parameters related to sympathetic responses to stress were investigated.

Results: Relative to sham, tcVNS paired to traumatic script stress decreased sympathetic function as measured by: decreased heart rate (-5.6%; ±3.6%, p<0.01), increased photoplethysmogram amplitude (peripheral vasodilation) (30.8%; ±28%, p<0.05), and increased pulse arrival time (vascular function) (6.2%; ±1.9%, p<0.0001). Similar (p < 0.05) autonomic, cardiovascular, and vascular effects were observed when tcVNS was applied after mental stress or without acute stress.

Conclusion: tcVNS attenuates sympathetic arousal associated with stress related to traumatic memories as well as mental stress in patients with PTSD, with effects persisting throughout multiple traumatic stress and stimulation testing days. These findings show that tcVNS has beneficial effects on the underlying neurophysiology of PTSD. Such autonomic metrics may also
be evaluated in daily life settings in tandem with tcVNS therapy to provide closed-loop delivery and measure efficacy.

Keywords: posttraumatic stress disorder, wearable bioelectronic medicine, vagal nerve stimulation, transcutaneous cervical stimulation, stress
Introduction

Posttraumatic stress disorder (PTSD) has a lifetime prevalence of 8% and is associated with considerable morbidity, loss of productivity, and treatment costs (Kilpatrick et al., 2013). Less than half of patients with PTSD seek or receive treatment, with existing treatment options exhibiting high (24%) dropout rates due to insufficient time with the mental health professional, treatment ineffectiveness, work interference, personal problems, or discomfort (Hoge et al., 2014). Cognitive behavioral therapy with prolonged exposure is an effective method to improve the PTSD symptoms in some patients, but requires considerable expertise, time, and resources (R. Bradley, Greene, Russ, Dutra, & Westen, 2005; Cukor, Olden, Lee, & Difede, 2010). In addition, psychiatrists may hesitate to employ exposure therapies due to concerns about decompensation, discomfort in using exposure, and patients’ reluctance regarding re-exposure to traumatic reminders (Becker, Zayfert, & Anderson, 2004; Cahill, Foa, Hembree, Marshall, & Nacash, 2006). Pharmacological treatments represent another standard of treatment although questions persist regarding their efficacy (Hoskins et al., 2015; Kelmendi et al., 2016; Krystal et al., 2017). New, evidence-based treatments that align well with the clinical needs of those with PTSD are needed (Frayne et al., 2011; Medicine, 2014; Steenkamp, Litz, Hoge, & Marmar, 2015).

In patients with PTSD, exposure to events or stress—particularly those with salient characteristics related to previously experienced trauma—can elicit symptoms such as hyperarousal, intrusive thoughts, avoidance behaviors, and dissociation (Nemeroff et al., 2006). This adverse response can lead to elevated inflammatory marker concentrations, impaired autonomic modulation, memory deficits, changes in brain morphology, and increased neural reactivity in emotion-specific brain areas (Bremner et al., 1997; Bremner, Narayan, et al., 1999;
Bremner et al., 1993; Bremner, Staib, et al., 1999; Gill, Saligan, Woods, & Page, 2009; Kitayama, Vaccarino, Kutner, Weiss, & Bremner, 2005; Nemeroff et al., 2006; Shah et al., 2013; Sherin & Nemeroff, 2011; Yehuda & LeDoux, 2007). Vagal nerve stimulation (VNS) is a potential treatment method for PTSD as it decreases sympathetic tone and related cardiovascular reactivity (Ardell, Rajendran, Nier, KenKnight, & Armour, 2015; George et al., 2000; Peña et al., 2014; Peña, Engineer, & McIntyre, 2013); however, it is limited by the cost and inconvenience of surgical procedures (Aaronson, Sears, Ruvuna, Bunker, & Conway, 2017; Bremner & Rapaport, 2017). Recent advances in noninvasive neuromodulation technologies are promising for widespread use of VNS.

Transcutaneous VNS devices noninvasively target vagal projections in the ear (auricular branch of the vagus) and neck (cervical branch in the carotid sheath). Auricular tVNS (taVNS) devices modulate central and peripheral physiology, as observed with the monitoring of peripheral physiological parameters, blood biomarkers, and brain imaging (Badran, Dowdle, et al., 2018; Ben-Menachem, Revesz, Simon, & Silberstein, 2015; Frangos, Ellrich, & Komisaruk, 2015; Garcia et al., 2017; Hamer & Bauer, 2019; Warren et al., 2019; Yakunina, Kim, & Nam, 2017). taVNS also has been shown to ameliorate tinnitus (Steenerson & Cronin, 2003; Yakunina, Kim, & Nam, 2018), episodic migraine (Garcia et al., 2017), seizure frequency (Hamer & Bauer, 2019), cluster headache (Reuter, McClure, Liebler, & Pozo-Rosich, 2019), and major depression (Fang et al., 2016; Rong et al., 2016), as well as improving vagal tone, deactivation of limbic and temporal brain structures, and mood enhancement in healthy populations and patients with PTSD (Badran, Mithoefer, et al., 2018; Bretherton et al., 2019; Clancy et al., 2014; Kraus et al., 2007; Lamb, Porges, Lewis, & Williamson, 2017). Fewer studies have looked at cervical tVNS (tcVNS), although they have been shown to reliably activate vagal nerve fibers (Frangos &
Komisaruk, 2017; Mourdoukoutas, Truong, Adair, Simon, & Bikson, 2017), and to produce anti-inflammatory effects (Brock et al., 2017; Lerman et al., 2016), with possible clinical utility in migraine and trigeminal allodyna (Chen et al., 2016; Oshinsky, Murphy, Hekierski, Cooper, & Simon, 2014). We have recently explored pairing of tcVNS with personalized traumatic script stress and non-personalized mental stress (public speaking, mental arithmetic) in healthy individuals with a history of exposure to psychological trauma without the current diagnosis of PTSD, and shown a reduction in cardiovascular reactivity and peripheral sympathetic activity both for personalized traumatic script and neutral mental stress as well as in the absence of stress exposure (Nil Z. Gurel et al., 2020). The current study examined the physiological effects of tcVNS in patients with PTSD during a series of stress tasks including personalized traumatic scripts, mental arithmetic, and public speech. The physiological measurements included the collection of electrocardiography (ECG), seismocardiography (SCG), photoplethysmography (PPG), respiration (RSP), electrodermal activity (EDA), and blood pressure (BP). We hypothesized that tcVNS (but not sham stimulation) would attenuate the physiological responses to stress in PTSD.

Materials and Methods

Participants & Assessments

The study was approved by the Institutional Review Boards of Georgia Institute of Technology, Emory University, SPAWAR Systems Center Pacific, and the Department of Navy Human Research Protection Program and was conducted at the Emory University School of Medicine between May 2017 and October 2019 (ClinicalTrials.gov # NCT02992899). Participants aged between 18-70 years with current PTSD as determined by the Structured Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID) (First & Gibbon, 2004) were
recruited informed consent was obtained. Exclusion criteria were: pregnancy; meningitis; traumatic brain injury; neurological disorder; organic mental disorder; history of loss of consciousness greater than one minute; alcohol abuse or substance abuse based on the SCID within the past 12 months; current or lifetime history of schizophrenia, schizoaffective disorder, or bulimia, based on the SCID; a history of serious medical or neurological illness, such as cardiovascular, gastrointestinal, hepatic, renal, neurologic or other systemic illness; evidence of a major medical or neurological illness on physical examination or as a result of laboratory studies; active implantable device (i.e. pacemaker); carotid atherosclerosis; cervical vagotomy. The Clinician Administered PTSD Scale (CAPS) was administered to establish current PTSD diagnosis and quantitate severity of symptoms (Blake et al., 1995). Among 127 who were screened for eligibility (See Figure S1 for Consolidated Standards of Reporting Trials (CONSORT) diagram), data from 25 participants who met the inclusion criteria and participated in the study were analyzed. Table S1 presents the demographics data. The mean age was 35 (±13 SD) with 19 females. The active group participants (n=13) had a mean age of 33 (±12 SD) and included 12 females; sham group participants (n=12) had a mean age of 38 (±13 SD), with seven females. SCID was used to evaluate for possible co-morbid psychiatric diagnosis. In this sample, 13 (52%) met criteria for major depressive disorder (MDD, 6 current, 7 past), eight (32%) for generalized anxiety disorder, four (16%) for panic disorder, two (8%) for social phobia, two (8%) for current obsessive compulsive disorder, one (4%) for agoraphobia without panic disorder, one (4%) for body dysmorphia, three (12%) for past alcohol abuse or dependence, and one (4%) for a past substance induced anxiety disorder.

Study Protocol & Blinding
The three-day protocol has been detailed in prior work (Bremner, Narayan, et al., 1999; Nil Z. Gurel et al., 2020) and is summarized in Figure S2. In short, the first day included audible delivery of six traumatic stress and six neutral scripts inside a high-resolution positron emission tomography (HR-PET) scanner. A public speech and mental arithmetic task were completed during both days two and three. Stimulation (active or sham) was applied immediately after the termination of each traumatic stress script, public speech, and mental arithmetic tasks using previously published methods (Nil Z. Gurel et al., 2020). The researchers provided negative feedback that reminded participants of the time limit continuously for the non-personalized mental stress tasks (public speech and mental arithmetic) to exaggerate the stress effect. Each day also included application of stimulation without acute stress, two consecutive on day one and one following a 90-minute break on days two and three.

The active tCVNS or sham stimulus groups were constructed with an online randomizer using simple randomization with group allocation completed by an individual who dissociated from enrollment, data collection, or analysis. The devices were pre-numbered by the manufacturer who were not involved in the research. The participants, clinical staff, and researchers conducting data collection and signal processing were blinded to the stimulus type. Stimulus grouping (active or sham) was un-blinded for the interpretation of statistical analysis.

Transcutaneous Cervical Vagal Nerve Stimulation

Both active tCVNS and sham stimuli were administered using hand-held devices (GammaCore, ElectroCore, Basking Ridge, New Jersey) with identical appearance, placement, and operation, as detailed in prior work (N Z Gurel et al., 2019; Nil Z. Gurel et al., 2020). The peak voltage amplitudes for active and sham device were 30V and 14V, respectively. At the start of stimulation, the intensity was increased gradually until each participant instructed to stop. The
active group received 20.3V (± 7.5 SD), and sham group received 13.6V (± 1.4 SD) averaged across all uses.

**Physiological Monitoring**

As detailed in prior work (Nil Z. Gurel et al., 2020), physiological data were collected by the measurement of ECG, PPG, EDA, RSP, and BP. Continuous data were simultaneously transmitted to a data acquisition system at 2kHz sampling rate. Cuff-based systolic (SBP) and diastolic blood pressure (DBP) values were recorded periodically with an Omron blood pressure cuff for the specified intervals.

**Signal Processing & Parameter Extraction**

The physiological signals were processed in MATLAB (R2017b, Mathworks, Natick MA) and the following parameters were extracted: heart rate (HR), pre-ejection period (PEP), amplitude of PPG, pulse arrival time (PAT), respiration rate (RR), width (RW), respiration prominence (RP), low frequency and high frequency heart rate variability (LF HRV, HF HRV), non-linear heart rate variability (SD1, SD2), skin conductance level (Heidenreich et al.), skin conductance response (M. M. Bradley, Miccoli, Escrig, & Lang), frequency of non-specific skin conductance responses (fNSSCR), and latency of skin conductance response (LSCR). The reader is referred to (Nil Z. Gurel et al., 2020) for specific processing steps for each signal that matches the prior work, and (Etemadi & Inan, 2017; N. Z. Gurel, Jung, Hersek, & Inan, 2019; Hernandez, Riobo, Rozga, Abowd, & Picard, 2014; Vest et al., 2018) for the validity of methods. The extracted parameters are summarized as follows:

**Heart rate and heart rate variability measures:** Frequency-domain analysis and joint time-frequency analysis (Poincaré Method) were used to extract the autonomic measures LF HRV, HF
HRV, LF/HF HRV, SD1, SD2, SD1/SD2 values. Based on previous studies, the LF HRV and SD2 are a reflection of baroreflex sensitivity (BRS) (Sleight et al., 1995). Individuals with PTSD are reported to have reduced BRS in previous studies (Shah et al., 2013), therefore these biomarkers of BRS have been computed. As many HRV measures require at least 5 minute of continuous ECG signal, the comparisons from the start to the end of that days (during rest periods) were the focus of our analyses.

Pre-ejection period: PEP is determined by the ventricular electromechanical delay and isovolumic contraction period. As a cardiac timing interval inversely related to cardiac contractility, decreased PEP reflects increased cardiac β1 receptor stimulation and cardiac sympathetic activity (Kelsey, 2012; Newlin & Levenson, 1979).

PPG amplitude and pulse arrival times: Calculated the beat-by-beat amplitude of the peripheral blood volume pulse, photoplethysmogram (PPG) amplitude is a peripheral sympathetic activity index, reflecting the dilation or constriction of peripheral blood vessels. An increase in PPG amplitude suggests vasodilation at the local area where the signal is acquired from (index finger). PAT is the time delay between the electrical stimulation of the heart to the “foot” (or trough) of a distal arterial waveform (taken from the index finger). It is the sum of the pulse transit time (PTT), which is inversely related to blood pressure, and the PEP (Mukkamala et al., 2015). PPG amplitude and PAT are vascular-dominated measures among other factors (Allen, 2007; Millasseau, Ritter, Takazawa, & Chowienczyk, 2006).

Respiratory measures: Due to the role of the vagus nerve in efferent parasympathetic activity, respiratory measures that take part in the regulation of parasympathetic activity were extracted: respiratory rate (RR), width (RW), prominence (RP).
Electrodermal activity measures: Skin conductance level (SCL), skin conductance response (M. M. Bradley et al.), frequency of non-specific peaks (fNSSCR), and latency of SCR (LSCR) were extracted as sweat gland activity measures.

Blood pressure measures: Periodic values of SBP and DBP were used to find pulse pressure (PP) and mean arterial pressure (MAP) using a clinical grade upper arm BP cuff.

Statistical Analysis

The baseline characteristics between the device groups were compared in Table S2. For this comparison, normality was assessed using Shapiro-Wilk test. Student’s t-test, Wilcoxon rank-sum tests, and chi-squared tests were used for normal continuous, non-normal continuous, and categorical variables, respectively. Stimulation-only administrations (n = 2 on day one, n = 1 on days two and three) were expressed as change values (from baseline) for stimulation and post-stimulation intervals and subsequently averaged across days. For stress tasks, data during stress, stimulation, and post-stimulation intervals were extracted. Data were then averaged across stress types (six traumatic, two public speech, two mental arithmetic stressors) and change scores between intervals (stress, stimulation, post-stimulation) were computed. For mental tasks that require speaking (public speech, mental arithmetic), stress data were extracted during times without vocalizations (immediately before task) to avoid unwanted signal noise while talking. Longer intervals of ECG (exceeding three minutes), as extracted as baseline, following a break, and end of day were used to assess HRV changes. Four essential comparisons were performed to assess differences between the device groups: stimulation without stress, stimulation following traumatic stress, public speech stress, mental arithmetic stress. Data in bar plots represent raw (unadjusted) mean ± 95% confidence interval (95% CI). Mixed models with repeated measures included random effect for each participant, used an unstructured correlation matrix, and were
adjusted for age. The beta coefficients (β) from the mixed models indicate the adjusted average percent or absolute differences in active group compared to sham group. β were reported along with adjusted 95% CI and P-values in results and figure captions. A two-sided p<0.05 denoted statistical significance. All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC) and MATLAB (R2017b, Natick, MA).

**Results**

tcVNS consistently decreases SNS in absence of stress over multiple days.

Figure 1 presents the raw values for autonomic (SD1/SD2), cardiovascular (HR), and vascular (PPG Amplitude and PAT) tone. Compared to sham, active tcVNS increased SD1/SD2 (Figure 1A, post-stimulation, p=0.019), decreased HR (Figure 1B, p=0.009 following stimulation), increased PPG amplitude (inversely associated with peripheral sympathetic activity, Figure 1C, p=0.049 during stimulation; p=0.025 following stimulation), and increased PAT (inversely associated with peripheral sympathetic activity, Figure 1D, p=0.026 during stimulation). The results were similar when the days were evaluated separately (Figures S3 and S4).

tcVNS reduces sympathetic tone following exposure to personalized traumatic scripts

Stimulation following exposure to personalized traumatic scripts resulted in marked changes in autonomic reactivity, similarly to stimulation without stress. Figures 2A-C illustrate changes in from the baseline state for the three intervals: traumatic stress, stimulation, and post-stimulation, merged from all six traumatic stressors. Relative to sham, active tcVNS decreased HR (Figure 2A, p=0.003 during stimulation; p=0.013 following stimulation), increased PPG amplitude (Figure 2B, p=0.032 during stimulation), increased PAT (Figure 2C, p<0.001 during combined traumatic stress; p=0.045 during stimulation; p<0.001 following stimulation), indicating
attenuation in the elevated autonomic tone due to stress. These effects were not initially observed, as no differences (p > 0.05) were found between active and sham during the first traumatic script. Figure S5D-F presents the stress reactivity across each traumatic script for these biomarkers. tcVNS also decreased long-term heart rate variability after multiple traumatic stress and stimulation protocol: Following the repeated traumatic stress protocol, tcVNS decreased SD2 obtained from Poincaré plot (p = 0.0002; Figure 3).

\[ tcVNS \text{ affects cardiac contractility and heart rate variability following mental stress.} \]

Figures 4A-D summarize the effects of tcVNS when applied after two different mental stress tasks: public speech and mental arithmetic on the second and third days. SD1/SD2 increased during stimulation right after speech task (Figure 4A, inversely related to sympathetic activity, p = 0.033 during stimulation) and after mental arithmetic test (Figure 4B, p = 0.001 during stimulation).

Active tcVNS increased PEP (Figure 4C, inversely related to cardiac sympathetic activity) following stimulation compared to sham (p = 0.009), indicating a decrease in cardiac contractility and sympathetic activity. Active tcVNS also decreased PP following stimulation after the mental arithmetic task compared to sham (p = 0.049; Figure 3D), indicating a decrease in vascular reactivity

\[ \text{Discussion} \]

This study showed that tcVNS modulates autonomic, cardiovascular, and vascular measures in PTSD with or without exposure to traumatic and mental stress. While the broad interpretation of the changes due to tcVNS are similar (i.e., reduction of sympathetic tone at baseline and blocking sympathetic responses to stress), it appears to have stronger effects in PTSD than in
traumatized individuals without PTSD (Nil Z. Gurel et al., 2020). Additionally, the effects of tcVNS on vascular measures (i.e., PPG amplitude) persist as markers of autonomic changes with tcVNS independent of disease status.

Active tcVNS decreased sympathetic arousal as measured by autonomic, cardiovascular, and vascular measures across multiple days and types of stressors. Results were seen on the first day after multiple exposures to personalized traumatic script stress, and on the afternoons of the second and third days after exposure to mental stress challenges (public speaking, mental arithmetic) in the morning (Figures S3-S4). PPG amplitude was a persistent biomarker of stimulation regardless of the disease status. We found greater SD1/SD2 response to tcVNS agree than sham, while the other frequency domain metrics were not affected by tcVNS. While the biological significance of this measure/finding is not clear, it is complemented by auricular VNS studies in which frequency-domain HRV improved (Bretherton et al., 2019; Brock et al., 2017; Clancy et al., 2014). SD1/SD2 is a non-linear Poincaré-based HRV, which is less studied in literature, although another study noted that it is negatively associated with diabetes (Roy & Ghatak, 2013). Hemodynamic measures (BP, HR) have been studied more, and been mixed throughout tcVNS studies: tcVNS decreased HR in humans (Brock et al., 2017) and rats, albeit only momentarily (Chen et al., 2016). Other studies, however, have not observed any autonomic or cardiovascular changes (Oshinsky et al., 2014).

tcVNS improved recovery from traumatic stress (reduced HR, increased PAT) and decreased peripheral sympathetic activity (decreased PPG amplitude). The results except PPG amplitude (HR and PAT) differ from the healthy-cohort results for traumatic stress. Additionally, no difference in PEP or EDA were noted for the PTSD cohort. PAT reactivity to traumatic stress was comparable between the groups when data from only the first script was analyzed (Figure
S5A-C. With the merged data (Figure 2C), sham group experienced more reactivity to stress. Patients with PTSD fail to habituate to repeated exposure of stress (Lissek & van Meurs, 2015; Wessa & Flor, 2007). The therapeutic potential of tcVNS is shown by its effect in decreasing stress reactivity. These results suggest that repeated tcVNS enhances resilience in the face of repeated stress in patients with PTSD.

An interesting outcome compared to prior work was the decrease in SD2 in the active tcVNS group with PTSD (Figure 3), which might indicate increased BRS. Reduced BRS is associated with increased mortality, higher inflammation (Lampert et al., 2008), increased depressive symptoms (Vaccarino et al., 2008), and increased risk of myocardial infarction (Bigger et al., 1992; La Rovere, Bigger, Marcus, Mortara, & Schwartz, 1998), and lower BRS has been proposed as a risk stratification for multiple cardiac mortality conditions (La Rovere, 2000; La Rovere & Schwartz, 1997). It is also known that patients with PTSD have impaired autonomic modulation and autonomic inflexibility as measured by frequency-domain HRV (Shah et al., 2013). We observed dampened SD2, which may also support this concept regarding BRS as an important moderating factor (Bretherton et al., 2019).

Active tcVNS improved cardiac contractility recovery (PEP) following the speech task, which was previously observed for traumatic stress data in the healthy cohort. The PEP and HRV results combined with the lack of PPG amplitude-RR trends are remarkably different from the healthy cohort: similar PPG and RR recovery characteristics for mental stress and traumatic stress and no differences in HRV or PEP. The PEP results are particularly interesting. PEP is an index of effort-related cardiac activity (Kelsey, 2012), with greater PEP indicated decreased effort and cardiac sympathetic activation. PEP is responsive to tasks requiring effortful active coping (Kelsey, 2012), similar to the speech task, potentially indicating tcVNS mitigates effort.
during the speech task. PEP has been shown previously to respond differently to challenge or threat conditions, specifically resulting in decreases with challenge and minimal changes with threat (Wormwood et al., 2019). In the current study, PEP decreased with the speech task in both groups, and the decrease was mitigated with active tcVNS. There were no significant differences in PEP for the traumatic stress case. The traumatic stress perhaps could be regarded as threat for patients with PTSD. PEP outcomes for speech tasks and (the lack of) PEP outcomes for traumatic stress might be due to the perceptual differences for challenge versus threat (Seery, 2013). A comparison of previous works in PTSD notes more than double cortisol release with cognitive challenge (Bremner et al., 2003), compared to the cortisol levels with traumatic stress (Elzinga, Schmahl, Vermetten, van Dyck, & Bremner, 2003). Although there is no direct statistical comparison between these studies, the magnitude differences in cortisol levels are apparent.

Several aspects of this study might limit the generalization of the results. The active group was female-dominated due to the small sample size. However it is important to note that PTSD is twice more prevalent in females than males (Kessler, Sonnega, Bromet, Hughes, & Nelson, 1995). The timing of the stimulation is also relevant to consider in the interpretation of our results. Prior animal and human studies initiated the stimulation before or during the stimuli (Burger et al., 2017; Burger et al., 2016; Engineer, Riley, Seale, Vrana, & Shetake, 2011; Lamb et al., 2017; Pena et al., 2014). In our study, we stimulated immediately at the end of the exposure to stress in terms of listening to scripts or performing mental stress (Bremner, Narayan, et al., 1999; Shah et al., 2013). Given instructions to hold images of trauma in the mind, and based on our prior work showing that physiological indicators of stress persist after termination of the task, we feel that this timing corresponds to the peak period of stress as experienced by the
individual. Our findings on the effects of tcVNS using this protocol on autonomic function, however, are consistent with prior preclinical and clinical studies of VNS using various stimulation timings and protocols (Bretherton et al., 2019; Lamb et al., 2017; Noble et al., 2017; Pena et al., 2014; Peña et al., 2013). Future studies should compare stimulation before, during, and at the termination of stress protocols.

In summary, using a multimodal sensing approach, we found that tcVNS at rest and paired with various stressors modulates the autonomic nervous system and cardiovascular reactivity. We demonstrated feasibility of use of wearable sensing devices for measurement of novel physiological markers in patients with PTSD. These modalities can be used in a home setting to assess target engagement and treatment efficacy for personalized neuromodulation. Future studies should focus on longitudinal studies to utilize these modalities in assessment of response to neuromodulation treatments in PTSD.

Acknowledgments: This work was supported by the Defense Advanced Research Projects Agency (DARPA), Arlington, VA, under Cooperative Agreement N66001-16-2-4054. Dr. Shah is sponsored by the National Institutes of Health, Award K23 HL127251.

Disclosures: Dr. Bremner reported having funding support from ElectroCore LLC. Other authors reported no potential conflicts of interests.

References


Badran, B. W., Dowdle, L. T., Mithoefer, O. J., LaBate, N. T., Coatsworth, J., Brown, J. C., . . . George, M. S. (2018). Neurophysiologic effects of transcutaneous auricular vagus nerve stimulation (taVNS) via electrical


**FIGURES**

**Autonomic**

![Image](image1.png)

**Cardiovascular**

![Image](image2.png)

**Vascular**

![Image](image3.png)

**Figure 1. tcVNS without acute stress:** Outcomes for stimulation without acute stress, merged from all days. Bars represent the unadjusted mean changes from baseline, error bars: 95% CI, values calculated from raw data, * indicates p<0.05. Active tcVNS group experienced the following relative to sham after adjustments: (A) The ratio of short-term variability to long-term variability (SD1/SD2) increased following stimulation by 14.1% (±11.6%, p=0.019). (B) HR decreased following stimulation by 2.7% (±2.0%, p=0.009). (C) PPG amplitude increased during stimulation by 43.4% (±43.4%, p=0.049) and following stimulation by 73.1% (±63.2%, p=0.025). (D) PAT increased during stimulation by 2.5% (±2.2%, p=0.026).
Figure 2. tcVNS after traumatic stress: Outcomes for stimulation following traumatic stress (all six scripts). Bars represent the unadjusted mean changes from baseline, error bars: 95% CI, values calculated from raw data, * indicates p<0.05. Active tcVNS group experienced the following relative to sham after traumatic stress after adjustments: (A) HR decreased during stimulation by 5.6% (±3.6%, p=0.003), and following stimulation by 3.9% (±3.0%, p=0.013). (B) PPG amplitude increased during stimulation by 30.8% (±28.0%, p=0.032). (C) PAT decreased less during traumatic stress by 9.2% (±3.0%, p<0.0001), stimulation by 2.2% (±2.2%, p=0.045), and following stimulation by 6.2% (±1.9%, p<0.0001).
**Figure 3.** Change in long-term heart rate variability (SD2) for multiple stimulation protocol following traumatic stress (four traumatic stress and six stimulation administrations on the first day). Bars represent the unadjusted mean changes from baseline, error bars: 95% CI, values calculated from raw data, * indicates p<0.05. Active tcVNS group experienced decrease in SD2 after the multiple stress protocol by 31.7ms (±15.5ms, p=0.0002) after adjustments.
Figure 4. tcVNS after mental stress: Outcomes for stimulation following two types of mental stress, public speech and mental arithmetic. Bars represent the unadjusted mean changes from baseline, error bars: 95% CI, values calculated from raw data, * indicates p<0.05. Active tcVNS group experienced the following relative to sham after adjustments: (A) SD1/SD2 increased during stimulation right after speech task by 23.1% (±21.1%, p=0.033). (B) Similar to the speech task, SD1/SD2 increased by 41.2% (±22.5%, p=0.001). (C) PEP increased following stimulation after speech task by 6.8% (±5%, p=0.009). (D) PP decreased following stimulation after mental arithmetic by 9.6% (±9.7%, p=0.049).
**SUPPLEMENTARY FIGURES**

**Figure S1.** Consolidated Standards of Reporting Trials (CONSORT) diagram of the study.
Figure S2. Protocol description. (A) The first day included traumatic stress through headphones. After each traumatic stress prompt, stimulation (active or sham) was applied immediately. (B) Second and third days included two types of mental stress, public speech and mental arithmetic. After each stressor, stimulation was applied immediately. After a 90-minute break from the mental stress protocol, participants received stimulation without acute stress.
Figure S3. tcVNS without acute stress, data from the first day. Bars represent the unadjusted mean changes from baseline, error bars: 95% CI, values calculated from raw data, * indicates p<0.05. Active tcVNS group experienced the following relative to sham after adjustments: (A) Increase in SD1/SD2 following stimulation by 21.9% (±21.9%, p=0.048). (B) Decrease in HR during stimulation by 3.9% (±3.7%, p=0.023), and following stimulation by 4.3% (±4.2%, p=0.035). (C) PPG amplitude increased following stimulation by 121.2% (±112.5%, p=0.047). (D) PAT increased during stimulation by 4.9% (±3.1%, p=0.003), and following stimulation by 3.8% (±3.4%, p=0.023).
Figure S4. tcVNS without acute stress, data from the second and third days. Bars represent the unadjusted mean changes from baseline, error bars: 95% CI, values calculated from raw data, * indicates p<0.05. Active tcVNS group experienced the following relative to sham after adjustments: (A) Short-term-variability (SD1) increased following stimulation by 20.3% (±16.5%, p=0.018) (C) HR decreased following stimulation by 4% (±2.9%, p=0.007). (C) PPG amplitude increased during stimulation by 0.18a.u. (±0.1a.u., p=0.004), and following stimulation by 0.23a.u. (±0.1a.u., p=0.003).
Figure S5. Unadjusted mean changes ± 95% confidence interval for the first traumatic stress script and the change in traumatic stress reactivity (or habituation) from the first to the sixth script between the groups (D-F). (A) No significant difference in HR between groups in any of the intervals. (B) No significant difference in PPG amplitude between groups in any of the intervals. (C) PAT increased during stimulation by 3.3% (±2.9%, p=0.027), and following stimulation by 4.2% (±2.9%, p=0.005) after adjustments indicating attenuation in the elevated autonomic tone due to stress. (D) HR reactivity to traumatic stress scripts as the protocol transitions from the first to the sixth script. (E) PPG amplitude reactivity. (F) PAT reactivity. * indicates p < 0.05
**SUPPLEMENTARY TABLES**

<table>
<thead>
<tr>
<th>ID Number</th>
<th>Device Type</th>
<th>Age [years]</th>
<th>Sex [F/M]</th>
<th>Height [cm]</th>
<th>Weight [kg]</th>
<th>BMI [kg/m²]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>active</td>
<td>22</td>
<td>F</td>
<td>165.1</td>
<td>59.0</td>
<td>21.6</td>
</tr>
<tr>
<td>2</td>
<td>active</td>
<td>27</td>
<td>F</td>
<td>154.9</td>
<td>57.6</td>
<td>24.0</td>
</tr>
<tr>
<td>3</td>
<td>active</td>
<td>34</td>
<td>F</td>
<td>172.7</td>
<td>59.0</td>
<td>19.8</td>
</tr>
<tr>
<td>4</td>
<td>active</td>
<td>23</td>
<td>F</td>
<td>170.2</td>
<td>112.5</td>
<td>38.8</td>
</tr>
<tr>
<td>5</td>
<td>active</td>
<td>25</td>
<td>F</td>
<td>170.2</td>
<td>58.1</td>
<td>20.0</td>
</tr>
<tr>
<td>6</td>
<td>active</td>
<td>42</td>
<td>F</td>
<td>166.4</td>
<td>58.1</td>
<td>21.0</td>
</tr>
<tr>
<td>7</td>
<td>active</td>
<td>55</td>
<td>F</td>
<td>165.1</td>
<td>90.7</td>
<td>33.3</td>
</tr>
<tr>
<td>8</td>
<td>active</td>
<td>49</td>
<td>F</td>
<td>165.1</td>
<td>73.0</td>
<td>26.8</td>
</tr>
<tr>
<td>9</td>
<td>active</td>
<td>19</td>
<td>F</td>
<td>165.1</td>
<td>81.6</td>
<td>29.9</td>
</tr>
<tr>
<td>10</td>
<td>active</td>
<td>45</td>
<td>M</td>
<td>193.0</td>
<td>108.9</td>
<td>29.2</td>
</tr>
<tr>
<td>11</td>
<td>active</td>
<td>21</td>
<td>F</td>
<td>157.5</td>
<td>65.8</td>
<td>26.5</td>
</tr>
<tr>
<td>12</td>
<td>active</td>
<td>23</td>
<td>F</td>
<td>160.0</td>
<td>54.4</td>
<td>21.3</td>
</tr>
<tr>
<td>13</td>
<td>active</td>
<td>45</td>
<td>F</td>
<td>177.8</td>
<td>137.0</td>
<td>43.3</td>
</tr>
<tr>
<td>14</td>
<td>sham</td>
<td>29</td>
<td>M</td>
<td>182.9</td>
<td>106.6</td>
<td>31.9</td>
</tr>
<tr>
<td>15</td>
<td>sham</td>
<td>46</td>
<td>F</td>
<td>167.6</td>
<td>70.3</td>
<td>25.0</td>
</tr>
<tr>
<td>16</td>
<td>sham</td>
<td>25</td>
<td>F</td>
<td>154.9</td>
<td>63.5</td>
<td>26.4</td>
</tr>
<tr>
<td>17</td>
<td>sham</td>
<td>32</td>
<td>M</td>
<td>177.8</td>
<td>108.9</td>
<td>34.4</td>
</tr>
<tr>
<td>18</td>
<td>sham</td>
<td>30</td>
<td>M</td>
<td>188.0</td>
<td>123.8</td>
<td>35.0</td>
</tr>
<tr>
<td>19</td>
<td>sham</td>
<td>47</td>
<td>F</td>
<td>162.6</td>
<td>81.6</td>
<td>30.9</td>
</tr>
<tr>
<td>20</td>
<td>sham</td>
<td>42</td>
<td>F</td>
<td>180.3</td>
<td>127.0</td>
<td>39.0</td>
</tr>
<tr>
<td>21</td>
<td>sham</td>
<td>26</td>
<td>F</td>
<td>175.3</td>
<td>68.0</td>
<td>22.1</td>
</tr>
<tr>
<td>22</td>
<td>sham</td>
<td>22</td>
<td>M</td>
<td>180.3</td>
<td>93.0</td>
<td>28.6</td>
</tr>
<tr>
<td>23</td>
<td>sham</td>
<td>40</td>
<td>F</td>
<td>160.0</td>
<td>68.0</td>
<td>26.6</td>
</tr>
<tr>
<td>24</td>
<td>sham</td>
<td>70</td>
<td>M</td>
<td>185.4</td>
<td>93.0</td>
<td>27.0</td>
</tr>
<tr>
<td>25</td>
<td>sham</td>
<td>42</td>
<td>F</td>
<td>154.9</td>
<td>63.5</td>
<td>26.5</td>
</tr>
</tbody>
</table>

**Table. S1.** Anthropometric information per participant. F, female; M, male; BMI, body mass index.
Table S2. Anthropometric and physiological parameter information per device group. P: p-value for the comparison between groups.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Active</th>
<th>Sham</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age [years]</td>
<td>33.1 (12.0)</td>
<td>37.6 (12.8)</td>
<td>0.21</td>
</tr>
<tr>
<td>Sex [F, %]</td>
<td>12F, 92.3%</td>
<td>7F, 58.3%</td>
<td>0.06</td>
</tr>
<tr>
<td>Height [cm]</td>
<td>167.9 (9.3)</td>
<td>172.5 (11.4)</td>
<td>0.31</td>
</tr>
<tr>
<td>Weight [kg]</td>
<td>78.1 (25.5)</td>
<td>88.9 (22.3)</td>
<td>0.13</td>
</tr>
<tr>
<td>BMI [kg/m²]</td>
<td>27.3 (7.1)</td>
<td>29.5 (4.7)</td>
<td>0.42</td>
</tr>
<tr>
<td>HR [bpm]</td>
<td>74.4 (10.9)</td>
<td>68.8 (11.0)</td>
<td>0.23</td>
</tr>
<tr>
<td>PEP [ms]</td>
<td>77.5 (55.0)</td>
<td>80.6 (34.5)</td>
<td>0.87</td>
</tr>
<tr>
<td>PPG [V]</td>
<td>0.3 (0.3)</td>
<td>0.3 (0.3)</td>
<td>0.57</td>
</tr>
<tr>
<td>RR [rpm]</td>
<td>16.9 (3.8)</td>
<td>17.5 (4.5)</td>
<td>0.71</td>
</tr>
<tr>
<td>RW [s]</td>
<td>2.0 (0.6)</td>
<td>1.8 (0.5)</td>
<td>0.32</td>
</tr>
<tr>
<td>RP [V]</td>
<td>0.7 (0.8)</td>
<td>0.7 (0.9)</td>
<td>0.72</td>
</tr>
<tr>
<td>PAT [ms]</td>
<td>264.2 (15.1)</td>
<td>272.8 (11.6)</td>
<td>0.14</td>
</tr>
<tr>
<td>HF HRV [ms²]</td>
<td>611.7 (532.0)</td>
<td>879.9 (668.3)</td>
<td>0.35</td>
</tr>
<tr>
<td>LF HRV [ms²]</td>
<td>738.4 (645.2)</td>
<td>799.5 (529.9)</td>
<td>0.60</td>
</tr>
<tr>
<td>LF/HF [n.u.]</td>
<td>1.7 (1.4)</td>
<td>1.2 (0.8)</td>
<td>0.58</td>
</tr>
<tr>
<td>SD1 [ms]</td>
<td>22.7 (15.0)</td>
<td>27.0 (13.0)</td>
<td>0.48</td>
</tr>
<tr>
<td>SD2 [ms]</td>
<td>57.9 (25.2)</td>
<td>64.7 (22.0)</td>
<td>0.51</td>
</tr>
<tr>
<td>SD1/SD2 [a.u.]</td>
<td>378.9 (160.0)</td>
<td>405.2 (113.7)</td>
<td>0.67</td>
</tr>
<tr>
<td>SBP [mmHg]</td>
<td>126.8 (22.2)</td>
<td>130.4 (17.1)</td>
<td>0.57</td>
</tr>
<tr>
<td>DBP [mmHg]</td>
<td>77.5 (13.6)</td>
<td>74.8 (9.1)</td>
<td>0.79</td>
</tr>
<tr>
<td>PP [mmHg]</td>
<td>49.4 (10.8)</td>
<td>55.7 (12.0)</td>
<td>0.25</td>
</tr>
<tr>
<td>SCLMEAN [μS]</td>
<td>2.9 (2.9)</td>
<td>4.3 (6.1)</td>
<td>0.50</td>
</tr>
<tr>
<td>SCLSLOPE[μS/s]</td>
<td>0.3 (0.7)</td>
<td>3.5 (8.5)</td>
<td>0.12</td>
</tr>
<tr>
<td>fNSSCR [pks/s]</td>
<td>0.4 (0.3)</td>
<td>0.4 (0.3)</td>
<td>0.97</td>
</tr>
<tr>
<td>LSCR [s]</td>
<td>15.5 (8.7)</td>
<td>24.1 (19.3)</td>
<td>0.62</td>
</tr>
</tbody>
</table>